阿尔茨海默病中的神经原纤维变性:从分子机制到药物靶点的鉴定

Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.

作者信息

Pei Jin-Jing, Sjögren Magnus, Winblad Bengt

机构信息

Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, KI-ADRC, Novum, Stockholm, Sweden.

出版信息

Curr Opin Psychiatry. 2008 Nov;21(6):555-61. doi: 10.1097/YCO.0b013e328314b78b.

Abstract

PURPOSE OF REVIEW

Great progress has been made in understanding the pathogenesis of neurofibrillary degeneration in Alzheimer's disease brains in the last two decades. In this review we summarize how neurons are degenerated in Alzheimer's disease brains and highlight the evidence of using kinases such as glycogen synthase kinase 3 and p70 S6 kinase and phosphatases such as protein phosphatase 2A as drug targets to prohibit the formation of neurofibrillary degeneration of Alzheimer's disease.

RECENT FINDINGS

In general there are two types of neuronal degeneration in Alzheimer's disease brains: neurofibrillary formation and apoptosis. The microtubule-associated protein tau that stabilizes neuronal microtubules under normal physiological conditions is abnormally hyperphosphorylated in Alzheimer's disease brains, resulting in the generation of aberrant aggregates that are toxic to neurons. The processes of tau hyperphosphorylation and the formation of neurofibrillary tangles are caused by the imbalance of the activities of protein kinases and protein phosphatases in Alzheimer's disease brains. Recent findings from our and other groups have suggested glycogen synthase kinase 3 and p70 S6 kinase as main tau kinases and protein phosphatase 2A as the main tau phosphatase involved in the formation of these processes. Activities of these targets are implicated by Abeta peptide, the major component of another hallmark in Alzheimer's disease brains, senile plaques.

SUMMARY

To prevent the clinical progression of neurodegeneration, a combination strategy is suggested to target both senile plaques with immunization and neurofibrillary tangles with drugs to prevent the synthesis and phosphorylation of tau.

摘要

综述目的

在过去二十年里,我们对阿尔茨海默病大脑中神经纤维变性的发病机制有了很大进展。在本综述中,我们总结了阿尔茨海默病大脑中神经元是如何退化的,并强调了将糖原合酶激酶3、p70 S6激酶等激酶以及蛋白磷酸酶2A等磷酸酶作为药物靶点来阻止阿尔茨海默病神经纤维变性形成的证据。

最新发现

一般来说,阿尔茨海默病大脑中有两种神经元退化类型:神经纤维形成和细胞凋亡。在正常生理条件下稳定神经元微管的微管相关蛋白tau在阿尔茨海默病大脑中异常过度磷酸化,导致产生对神经元有毒的异常聚集体。tau过度磷酸化和神经纤维缠结的形成过程是由阿尔茨海默病大脑中蛋白激酶和蛋白磷酸酶活性失衡引起的。我们和其他研究小组的最新发现表明,糖原合酶激酶3和p70 S6激酶是主要的tau激酶,蛋白磷酸酶2A是参与这些过程形成的主要tau磷酸酶。这些靶点的活性与淀粉样β肽有关,淀粉样β肽是阿尔茨海默病大脑中另一个标志性特征老年斑的主要成分。

总结

为了防止神经变性的临床进展,建议采用联合策略,即通过免疫靶向老年斑,通过药物靶向神经纤维缠结,以防止tau的合成和磷酸化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索